1. Home
  2. UAMY vs VOGX Comparison

UAMY vs VOGX Comparison

Compare UAMY & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United States Antimony Corporation

UAMY

United States Antimony Corporation

N/A

Current Price

$2.81

Market Cap

458.0M

Sector

Industrials

ML Signal

N/A

Logo Vogenx Inc Common Stock

VOGX

Vogenx Inc Common Stock

N/A

Current Price

$17.42

Market Cap

482.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UAMY
VOGX
Founded
1968
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
458.0M
482.8M
IPO Year
1997
2026

Fundamental Metrics

Financial Performance
Metric
UAMY
VOGX
Price
$2.81
$17.42
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
★ $10.92
N/A
AVG Volume (30 Days)
★ 6.0M
69.8K
Earning Date
11-20-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $39,257,708.00
N/A
Revenue This Year
$65.44
N/A
Revenue Next Year
$210.77
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 162.80
N/A
52 Week Low
$2.64
$13.50
52 Week High
$12.64
$38.41

Technical Indicators

Market Signals
Indicator
UAMY
VOGX
Relative Strength Index (RSI) 38.29 43.83
Support Level $2.64 $14.41
Resistance Level $3.37 $22.10
Average True Range (ATR) 0.25 2.63
MACD 0.03 0.31
Stochastic Oscillator 32.76 38.73

Price Performance

Historical Comparison
UAMY
VOGX

About UAMY United States Antimony Corporation

United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the Domestic, Canada, and Mexico, of which the vast majority of its revenue comes from the Domestic.

About VOGX Vogenx Inc Common Stock

Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.

Share on Social Networks: